![Takehide Iwasa](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Takehide Iwasa
Direttore/Membro del Consiglio presso Karydo TherapeutiX, Inc.
Profilo
Takehide Iwasa is currently a Director at Karydo TherapeutiX, Inc., Allgene, Inc., and Biomedica Solution KK.
He was previously a Director & General Manager-Sales at tella, Inc.
Posizioni attive di Takehide Iwasa
Società | Posizione | Inizio |
---|---|---|
Karydo TherapeutiX, Inc.
![]() Karydo TherapeutiX, Inc. Miscellaneous Commercial ServicesCommercial Services Karydo TherapeutiX, Inc. develops technologies to detect the earliest signs of diseases. Its proprietary technology includes “iOrgans Technology.” This technology consists of three sub-technologies: Reverse-iOrgans (R-iOrgans,) Forward-iOrgans (F-iOrgans) and Drug-iOrgans (D-iOrgans.) They all use iOrgans Indicators (iOrgans-Id) to effectively and efficiently detect the earliest signs of diseases (R-iOrgans,) and to pre-empt them (F-iOrgans.) This technology can be also used to discover effects of drugs (D-iOrgans.) The company was founded by Thomas Sato on October 15, 2015 and is headquartered in Tokyo, Japan. | Direttore/Membro del Consiglio | 01/10/2015 |
Allgene, Inc. | Direttore/Membro del Consiglio | 01/12/2015 |
Biomedica Solution KK
![]() Biomedica Solution KK BiotechnologyHealth Technology Part of Tella, Inc., Biomedica Solution KK is a Japanese company that manufactures cell production facilities. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Takehide Iwasa
Società | Posizione | Fine |
---|---|---|
TELLA, INC. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
Karydo TherapeutiX, Inc.
![]() Karydo TherapeutiX, Inc. Miscellaneous Commercial ServicesCommercial Services Karydo TherapeutiX, Inc. develops technologies to detect the earliest signs of diseases. Its proprietary technology includes “iOrgans Technology.” This technology consists of three sub-technologies: Reverse-iOrgans (R-iOrgans,) Forward-iOrgans (F-iOrgans) and Drug-iOrgans (D-iOrgans.) They all use iOrgans Indicators (iOrgans-Id) to effectively and efficiently detect the earliest signs of diseases (R-iOrgans,) and to pre-empt them (F-iOrgans.) This technology can be also used to discover effects of drugs (D-iOrgans.) The company was founded by Thomas Sato on October 15, 2015 and is headquartered in Tokyo, Japan. | Commercial Services |
Allgene, Inc. | |
Biomedica Solution KK
![]() Biomedica Solution KK BiotechnologyHealth Technology Part of Tella, Inc., Biomedica Solution KK is a Japanese company that manufactures cell production facilities. | Health Technology |
tella, Inc.
![]() tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
- Borsa valori
- Insiders
- Takehide Iwasa